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Opinion statement
The mainstay of treatment of epilepsy has been antiepileptic drugs; however, despite the
emergence of new agents, a consistent proportion remain drug-resistant. Newer AEDs show
promise. However, as it becomes clear that the epilepsies are a group of diseases rather than
a single disorder the prospect of targeted treatment in some may become a reality.
Introduction
Epilepsy is a condition characterized by recurrent epilep-
tic seizures; it is not a single condition, more accurately,
we should refer to the epilepsies as there are many dif-
ferent underlying causes and consequently differing un-
derlying pathophysiologies. Besides their common
name, the epilepsies also share common treatment op-
tions, as traditionally, epilepsy treatment consists of ther-
apies empirically known to raise seizure threshold rather
than targeted treatments of the underlying cause. Many
of the treatments widely in use today have been discov-
ered serendipitously to have anticonvulsive properties,
for example, agents such as phenobarbital or sodium
valproate [1]., or fasting as a precursor of the ketogenic
diet, and have since been used to treat a wide range of
epilepsy syndromes. Often, their efficacy has also been
validated in heterogeneous groups of patients, thus prob-
ably missing efficacy in specific epilepsy syndromes.
In recent years, great progress has been made in the
understanding of mechanisms by which different anticon-
vulsive treatments work either by decreasing neuronal ex-
citation or increasing neuronal inhibition at a synaptic
level. This has led to the discussion of rational polytherapy,
that is, utilization of a combination of drugs with different
rather than similar mechanisms of action. At the same
time, through the technology of next-generation sequenc-
ing, numerous gene mutations have been discovered as
causal in different epilepsy syndromes, and subsequent
functional studies have given insight into disease
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pathophysiology. Combining this knowledge, it has al-
ready been possible to identify some existing therapies as
being particularly beneficiary or on the other hand contra-
indicated for specific epilepsy syndromes, such as for ex-
ample the ketogenic diet as a targeted treatment providing
an alternative fuel to glucose for children with GLUT-1
deficiency while carbamazepine or lamotrigine as sodium
ion channel blockers may worsen seizures in children with
SCN1Amutations (e.g., Dravet syndrome). A better under-
standing of pathophysiology nurtures the hope of the
development of new, targeted antiepileptic treatments,
and efforts are already being made in this direction.
With antiepileptic treatments available today, 30 %
of epilepsy patients remain drug-resistant. This especially
concerns patients with early onset epileptic encephalop-
athies, not only having a poor prognosis for seizure
control but also an extremely poor prognosis for
neurodevelopmental outcome. It is evident that this
group of patients would have a lot to gain by early,
targeted treatment rather than the traditional trial and
error approach to epilepsy therapy. In this review, we
aim to provide the existing evidence for the use of
existing and some novel antiepileptic treatments as
targeted treatment for specific epilepsy syndromes.
Treatment
Ketogenic diet
& The ketogenic diet has been used for the treatment of the epilepsies for almost
100 years [2]. It was first utilized in 1921 by Wilder at the Mayo clinic based
on the discovery that fasting had been determined to help seizures. The
positive effect of fasting on seizures is documented as early as in the Hippo-
cratic collection. The Parisian physicians Guelpa and Marie first reported
starvation as an epilepsy treatment in modern age in 1911. This
metabolic state leads to the production of acetone and beta-
hydroxybutyric acid; ketonemia, however, could also be induced by
a diet containing a high proportion of fat with low carbohydrate
(including protein). Even though implementation of the ketogenic
diet led to encouraging results leading to it being widely used in
the 1920s and 1930s, it was then overshadowed by the discovery of
new antiepileptic drugs such as phenytoin and sodium valproate.
& Interest in the diet reemerged in the 1990s, and awide range of clinical data
has been published on its efficacy in treating children with drug-resistant
epilepsy. Still systematic reviews criticized the lack of randomized con-
trolled data [3–5]. The first randomized controlled trial proving the
efficacy of the ketogenic diet for the management of epilepsy in
children was only published in 2008 [6]. Neal et al. studied seizure
control in 145 children with refractory epilepsy randomly assigning
73 children to the ketogenic diet, while the other 72 had no change
to treatment. After 3 months, the mean percentage of baseline
seizures was significantly lower in the diet group (pG0.0001). An-
other randomized controlled trial conducted in 2013 [7••] proved
the efficacy of the modified Atkins diet for the treatment of refrac-
tory epilepsy in children, also showing the diet to be well tolerated.
The above studies showed responder rates (950 % seizure reduc-
tion) of 38 and 52 %, respectively. In specific epilepsies, a better
response may be seen. In one prospective open label study of
infantile spasms, a responder rate of 76 % was seen [8]. Of patients
with epilepsy due to focal malformations, 61.7 % were reported to
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respond to the ketogenic diet [9] and 60 % of patients with re-
fractive epilepsy due to hypoxic ischemic encephalopathy [10].
& The ketogenic diet remains the treatment of choice for glucose transporter
defects such as GLUT-1 deficiency syndrome [11•]. In this condi-
tion, delivery of glucose to the brain across the blood brain barrier
is insufficient as the primary glucose transporter GLUT-1 is im-
paired. In its most serious form, the syndrome results in a pheno-
type with early onset refractory epilepsy, developmental delay,
complex movement disorder and acquired microcephaly. The syn-
drome is due to mutations in the SLC2A1 gene on chromosome 1.
With the ketogenic diet, nutritional fat is transformed into ketone
bodies, which can be used as a metabolic substrate for the brain
instead of glucose, it constitutes a targeted treatment for GLUT-1
deficiency. The wide phenotypic spectrum of the disorder is now
becoming apparent; some children may have epilepsy responsive to
antiepileptic medication. It has been shown that SLC2A1 mutations
can also cause a phenotype of myoclonic astatic epilepsy (MAE)
accounting for 5 % of patients with MAE [12]. SLC2A1 mutations
have also been found in 1 % of a patient cohort with genetic
generalized epilepsy [13]. However; Ramm-Petersen et al. demon-
strated that early utilization of the diet may lead to improved
neurodevelopmental outcome. It is therefore crucial that the keto-
genic diet is used as first line treatment in these patients and is
implemented as early as possible. These findings stress the impor-
tance of determining the genetic etiology in epilepsy patients as this
might allow us to offer them early targeted treatment resulting in
better outcome.
& Research is ongoing in order to understand the exact mechanism the
ketogenic diet works in epilepsies other than GLUT-1 deficiency. This is
important as on the one hand it might allow us to predict the patients
likely to respond to the diet and on the other hand might make it possible
to identify a particular therapeutic agent that could be directly adminis-
tered thus releasing patients and their families of the diet’s restraints.
Recently promising results have been shown for the medium chain fatty
acid decanoic acid (C10) [14, 15].
Classical ketogenic diet
Standard procedure The classical ketogenic diet is based on a ratio of fat to carbohydrate and
protein, usually 3:1 or 4:1. The fat is provided by long-chain triglycerides,
protein is kept to minimum requirements for growth, and carbohydrate is very
restricted. Menus are calculated and foods have to be weighed to ensure
accuracy. Usually the diet is started on a 2:1 ratio and gradually increased to the
4:1 ratio as tolerated over 1–2 weeks. The diet is fully supplemented with
vitamins and minerals. Ketosis is monitored with urine reagent sticks or blood
ketone monitors.
Contraindications hyperlipidemia, renal stones, organic acid deficiency syndromes
Complications hunger, vomiting, diarrhea, abdominal pain, constipation (all of which can
usually be alleviated by manipulation of the diet), lack of energy, taste prob-
lems, renal stones.
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Special points: the ketogenic diet is proven effective in children with epi-
lepsy and is a highly effective targeted treatment for patients with known
SLC2A1 mutations.
Medium-chain triglyceride (MCT) ketogenic diet
Standard procedure In the MCT diet, long-chain fat is replaced by medium-chain fat from 30 %
(modified MCT diet) to 60 % (traditional MCT diet) of energy intake. As MCT
yieldsmore ketones per kilocalorie of energy than long-chain fatty acids, theMCT
diet allows for more protein and carbohydrates to be included in the diet. MCT is
usually started at 40–45 % of energy and increased up to 60 % if necessary and
tolerated. The diet is fully supplemented with vitamins and minerals.
Contraindications hyperlipidemia, renal stones, organic acid deficiency syndromes
Complications hunger, vomiting, diarrhea, abdominal pain, constipation (all of which can
usually be alleviated by manipulation of the diet), lack of energy, taste prob-
lems, renal stones, hypoglycemia.
Special points: the MCT diet allows a marginally higher protein and car-
bohydrate intake and showed comparable efficacy to the classical ketogenic
diet [16]. It may also be utilized where there is concern about
hypertriglyceridaemia
Modified ketogenic diet (MKD)
Standard procedure Amore relaxedway of giving the ketogenic diet. Carbohydrate intake is restricted to
10 g/day. The intake of fat is actively encouraged. Protein intake is not restricted.
This means that during cooking, weighing is restricted to food components con-
taining carbohydrates, while the rest of the food components can be added freely.
Carbohydrate-free foods can be offered to the patients unrestricted during the day.
Contraindications none
Complications constipation (46 %), anorexia (18 %), lethargy (6 %), vomiting (10 %) [7••]
Special points: Less restrictive alternative to the traditional ketogenic diet.
More suitable for older individuals and may improve compliance in long-
time treatment.
Low glycemic index treatment (LGIT)
Standard procedure High glycemic index (GI950) carbohydrates are eliminated from the diet and
total carbohydrates are limited to 40–60 g/day (approx. 10 % of daily calories).
Recommended goals for daily protein and fat intake are set to ensure that the
patient’s caloric needs aremet. Increased fat intake is still encouraged aiming for
a 20 % protein, 50–60 % fat diet.
Contraindications none
Complications minimal fatigue, vomiting, and lethargy have been reported [17]
Special points: A less restrictive alternative to the traditional ketogenic diet
might improve compliance in long-time treatment. Good efficacy has been
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reported in children with drug resistant epilepsy (66 % had seizure reduc-
tion 950 % over 12 months [17]), but no randomized controlled trials are
available.
Pharmacologic treatment
& Antiepileptic drugs (AED) still are the foundation of epilepsy therapy. This
is justified by their efficacy. Of individuals with newly diagnosed epilepsy,
50%will become seizure-free on amodest or moderate dose of their first
antiepileptic drug and another 10 %will be controlled on their second or
third drug [1]. Unfortunately, the remaining patients are at risk of devel-
oping drug-resistant epilepsy, and their overall percentage has failed to
reduce with the introduction of the new (third generation) AEDs [18],
despite some gains in tolerability and options for rational polytherapy.
& Since the serendipitous discovery of the anticonvulsant properties of
phenobarbital in 1912, the development of newAEDs has continued to
be largely based on screening newly synthesized agents for their anti-
convulsive effects using animal models for convulsive or
nonconvulsive seizures. Thus, we aremainly developing drugs targeting
seizures rather than the underlying pathology causing the patient’s
seizures. This has been problematic owing to the fact in many the
underlying cause of the epilepsy has been unknown.
& Below we will consider the evidence regarding newer pharmacological
agents used in childhood epilepsies (stiripentol, zonisamide,
perampanel, cannabidiol)
Stiripentol
Background Stiripentol was first studied as an add-on AED in a large exploratory
observational trial in 1999 showing a surprising favorable response espe-
cially in patients with Dravet syndrome. These results were confirmed in
two randomized placebo-controlled syndrome-dedicated trials investi-
gating the efficacy of stiripentol as adjunctive therapy to clobazam and
sodium valproate [19, 20]. In these two studies, adding stiripentol reduced
overall seizure rate by 70 %. There is evidence suggesting that stiripentol acts
both through an intrinsic GABAergic effect and through pharmacokinetic in-
teraction by inhibiting cytochrome P450 enzymes [21]. Stiripentol was desig-
nated an orphan drug by the European Medicine Agency (EMA) in 2001 and
obtained marketing authorization in 2007 Bfor use in conjunction with
clobazam and sodium valproate as adjunctive therapy of refractory generalized
tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy
(SMEI, Dravet’s syndrome)
Standard dosage initially 10mg/kg in 2–3 divided doses; titrate dose overminimum of 3 days to
max. 50 mg/kg/day in 2–3 divided doses (usually in practice introduced more
cautiously).
Contraindications history of psychosis.
Main drug interactions increases plasma concentration of clobazam, carbamazepine, fosphenytoin,
phenobarbital, phenytoin, primidone, sodium valproate
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Main side effects nausea, vomiting, aggression, anorexia, ataxia, drowsiness, dystonia, hyperex-
citability, hyperkinesia, hypotonia, irritability, sleep disorders, weight loss,
neutropenia; less commonly fatigue, photosensitivity, rash, and urticaria.
Special points: The combination of stiripentol, clobazam, and sodium
valproate is currently considered optimal therapy in patients with Dravet
syndrome with refractory generalized tonic-clonic seizures.
Zonisamide
Background Zonisamide is a benzisoxazole derivate acting through inhibition of
Na+ channels and reduction of T-type Ca2+ currents. Following a phase III,
double-blind, randomized, placebo-controlled, multicenter trial showing that
it is significantly more effective than placebo in controlling partial seizures in
children already receiving one or two other AEDs [22•]. It was recently ap-
proved for the adjunctive treatment of partial seizures (with or without sec-
ondary generalization) in children ≥6 years in Europe. Its safe use in children
has been further confirmed in a pooled analysis of 17 studies including 398
pediatric patients ≤16 years treated with zonisamide [23].
Standard dosage initially 1 mg/kg once daily for 7 days, then increased by 1 mg/kg every 7 days;
usual maintenance, body weight 20-55 kg, 6–8mg/kg once daily (max. 500mg
once daily), body weight over 55 kg, 300–500 mg once daily.
Contraindications hypersensitivity to sulfonamides, concomitant use of drugs that increase risk of
hyperthermia or metabolic acidosis.
Main drug interactions potent inducers of cytochrome P450 enzyme CYP3A4 such as carbamazepine,
phenytoin and phenobarbital increase zonisamide clearance and may necessi-
tate dose increase.
Main side effects decreased appetite, somnolence, fatigue, dizziness, decreased weight, renal
stones, irritability and headache. Patients aged 6–11 years (5 % of studied
patients): decreased appetite, somnolence, fatigue, irritability and lethargy;
while in those aged 12 to16 years, there was decreased appetite, fatigue,
somnolence, decreased weight, dizziness, headache, and insomnia [23].
Special points: Increase dose at 2-week intervals in patients who are not
receiving concomitant carbamazepine, phenytoin, phenobarbital, or other
potent inducers of cytochrome P450 enzyme CYP3A4. Carefully monitor
weight of pediatric patients treated with zonisamide.
Perampanel
Background One of the principles of rational polytherapy in the epilepsies is the combina-
tion of drugs with different, rather than the same, mechanisms of action.
Perampanel is the first drug in a novel class of AEDs, as it is a selective
noncompetitive AMPA-receptor antagonist [24] and thus is a valuable option as
an add-on therapy in a rational polytherapy concept. The AMPA-type glutamate
receptors modulate the generation and spread of epileptiform activity by
binding glutamate in the post-synaptic excitatory synapses [24]. In a double-
blind, placebo-controlled trial of perampanel as an add-on therapy in 143
adolescents (12–17 years) with drug resistant partial seizures perampanel
showed sustained seizure frequency improvements and a generally favorable
safety profile [25]. Data on efficacy and tolerability in a pediatric population
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also including younger children was published by Biró et al. The overall
responder rate (seizure reduction 950 %) in this retrospective study was 31 %
with a better efficacy in children 6 years and older (36 %) than in children
under 6 years (9 %) [26].
Standard dosage Child 12–18 years: initially 2 mg once daily before bedtime, increased accord-
ing to response and tolerability in 2-mg steps at intervals of at least 2 weeks;
usual maintenance 4–8 mg once daily; max. 12 mg once daily.
Contraindications severe hepatic impairment, moderate and severe renal impairment.
Main drug interactions Plasma concentration of perampanel reduced by carbamazepine, phenytoin,
fosphenytoin, oxcarbazepine and topiramate, and increased by ketoconazole.
Perampanel reduces plasma concentration of midazolam, increases plasma
concentration of oxcarbazepine and accelerates metabolism of progestogens.
Main side effects nausea, changes in appetite, weight increase, aggression, dizziness, drowsiness,
dysarthria, gait disturbance, irritability, anxiety, confusion, suicidal ideation
and behaviour, malaise, ataxia, back pain, vertigo, blurred vision, and diplopia.
Special points: Perampanel is the first noncompetitive AMPA-receptor, a
novel class of AEDs. It is licensed as an add-on therapy for patients over 12
years with drug-resistant focal seizures.
Cannabidiol (CBD)
Background Cannabis has historically been used to treat epilepsy. Recently, the interest for the
antiepileptic properties especially of cannabis’ nonpsychoactive compound
cannabidiol (CBD) has been rekindled in particular as an add-on therapy for the
treatment of the potentially devastating epileptic encephalopathies Dravet syn-
drome, Lennox-Gastaut syndrome (LGS) and infantile spasms (IS). Pharmaco-
logic studies have proposed TRP channels, G-coupled protein receptor protein 55
(GPR55), or voltage-dependent anion-selective channel protein 1 (VDAC1) as
possible targets through which CBD reduces neuronal excitability and neuronal
transmission [27]. Preclinical studies have shown CBD to have antiepileptiform
and anticonvulsant effects in vitro and in vivo models [27]. There are several
publications of parental reports on the efficacy of cannabidiol-enriched cannabis
extracts for children with Dravet syndrome, LGS or IS. These report good results
with an overall responder rate of 85 % with 14 % reporting complete seizure
freedom [28], 84%with 11% reporting complete seizure freedom [29] and 33%
(950% reduction in seizures) with a much higher responder rate of 89 % for the
LGS patients [30]. According to the parent surveys, CBD seemed to be tolerated
well by the patients and some reported added beneficial effects on sleep, alertness
andmood. These studies, however, are small, and are prone to bias. Randomized
clinical trials are required to evaluate efficacy of CBD in children with epilepsy as
well as to assess safety and appropriate dosing. Such studies are currently un-
derway for patients with Dravet syndrome and LGS.
Dosage currently ongoing trials in progress to determine optimal dose and tolerability.
Side effects as above.
Special points: CBD seems a promising add on therapy for patients with
devastating epileptic encephalopathies, but efficacy and safety have yet to
be proven in randomized clinical trials.
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Emerging therapies
& In recent years, next generation sequencing has proven highly effective
in revealing gene mutations causing genetic epilepsies [31•, 32]. This
has lead to functional studies eliciting the mechanism interrupted by
gene mutations and consequently to the identification of potential
targets for drug development. This development constitutes a
paradigm-changing approach to epilepsy therapy making targeted,
rather than empiric treatment a realistic prospect.
& Below, we will discuss the pharmacologic agents currently considered
for the treatment of specific genetic epilepsies. None of those treat-
ments are yet validated in the clinical setting.
Quinidine in KCNT1-related epilepsies
Background KCNT1 encodes a weak voltage-dependent and intracellular sodium-activated
potassium channel. Gain-of-function mutations in the KCNT1 gene have been
found to cause two distinct epilepsy phenotypes. Autosomal dominant noc-
turnal frontal lobe epilepsy (ADNFLE) [33•] and epilepsy of infancy with
migrating focal seizures (EIMFS) [34, 35]. Milligan et al. [36•] examined the
electrophysiological properties of KCNT1 mutations in Xenopus oocytes and
found all mutated channels to yield larger currents than the wild type. Muta-
tions found in patients with ADNFLE were associated with currents that were
approximately three times greater than the wild type, while the mutations
underlying the more severe phenotype of EIMFS were associated with currents
five times greater. The group then examined the effect of the anti-arrhythmic
drug quinidine, known to block KCNT1 channels [37], on the mutated chan-
nels and found it to normalize potassium conductance. Based on this knowl-
edge Bearden et al. treated a drug resistant patient with EIMFS with quinidine
and reported a dramatic reduction in seizure frequency and some develop-
mental improvement [38]. A further two patients with KCNT1 mutations
treated with quinidine were recently published by Mikati et al. Again, the
patient with EIMFS showed dramatic reduction in seizure frequency, while the
other with a novel phenotype showed no improvement [39].
Dosage In the case report mentioned, the patient was started on a dose of 2 mg/kg/day
followed by a 4 day dose titration up to 33 mg/kg/day divided into four doses.
After 6 weeks, the dose was further increased to 42 mg/kg/day due to seizure
recurrence. Serum quinidine levels ranged from 1.5–4 μg/ml (typical thera-
peutic range for arrhythmias=2–5 μg/ml and toxicity is thought to occur at
levels 96 μg/ml).
Special points: quinidine is not licensed as an AED.
Retigabine in KCNQ2-related epilepsies
Background KCNQ2-related disorders represent a continuum of overlapping neonatal epi-
leptic phenotypes caused by a heterozygous mutation in KCNQ2, the gene
encoding the potassium voltage-gated channel subfamily KQT member 2, also
known as Kv7.2. The clinical features of KCNQ2-related disorders range from
KCNQ2-related benign familial neonatal epilepsy (KCNQ2-BFNE) at the mild
end to KCNQ2-related epileptic encephalopathy (KCNQ2-NEE) at the severe
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end [40]. Retigabine is an AED currently used as adjunctive therapy in adults
with partial-onset seizures and is known to selectively enhance the function of
potassium channels formed by neuronal Kv7 subunits [41]. Experimental
studies have shown retigabine [42] aswell as retigabine derivative HN38 [43] to
significantly increase potassium currents in mutated KCNQ2 channels, sug-
gesting their potential as a targeted therapy for KCNQ2-related epilepsies.
Interestingly the KCNQ2-related epilepsies have recently been shown to re-
spond particularly well to drugs known to act on sodium channels including
carbamazepine and phenytoin, leading to them being proposed as first line
treatment in these epilepsies [44].
Fenfluramine in Dravet syndrome
Background Dravet syndrome, a severe childhood epilepsy characterized by persistent, often
drug-resistant seizures and progressive developmental delay is known to be caused
by mutations in the SCN1A gene encoding the voltage-gated sodium channel
subunit alpha NAV1.1. Fenfluramine is an amphetamine like drug that was
launched for obesity in the 1990s. Due to cardiac side effects (eg pulmonary
hypertension and heart valve disease) it was withdrawn from the market in 1997.
The drug acts through inhibition of serotonin uptake and by release of serotonin
due to a disruption of vesicular storage. Because of the high density of serotonin
receptors in structures critically involved in epilepsies, such as the hippocampus,
fenfluramine is believed to have an antiepileptic effect. In a recent study by Zhang
et al., it was proven to reduce epileptiform activity in zebrafish larvae with an
antisense knockdown of scn1Lab, which is the zebrafish analog to SCN1A [45].
After an earlier report by Boel et al. in 1996 [46], Ceuleman et al. trialed fenflur-
amine as an add-on treatment in 12 patients with Dravet syndrome over 1–19
years with remarkable results. Of the 12 patients, 8 were seizure-free at their last
follow up visit. Overall patients were seizure-free for a mean of 6 (1–19) years. No
serious adverse events occurred [47••]. Clinical trials are planned to evaluate the
effect of fenfluramine in a randomized controlled setting.
Memantine in GRIN2A-related epilepsies
Background Mutation in the GRIN2A gen encoding the GluN2A subunit of the NMDA
receptorss have been associated with several childhood-onset epilepsy syndromes
including disorders of the epilepsy-aphasia spectrum as well as some described
cases of early onset epileptic encephalopathy. The NMDAR antagonist memantine
was found to in vitro inhibit mutant channels with the mutation c.2434C9A,
resulting in a leucine to methionine substitution at residue 812. Administration of
the drug to a patient carrying this exact mutation led to a decrease in seizure
frequency and allowed for tapering of conventional AEDs. A different GluN2A
mutation (N615K) was proven sensitive to another NMDAR antagonist indicating
a need for specific evaluation of each mutant GRIN2A to evaluate response to
NMDAR antagonists [48]. Memantine is yet to be trialed clinically.
Compliance with Ethical Standards
Conflict of Interest
Katharina Vezyroglou declares no conflict of interest.
J. Helen Cross has a patent for C10 in the treatment of epilepsy; has received royalties for a chapter on childhood
epilepsy in Brain Diseases of the Nervous System, and as editor of Paediatric Epilepsy; has received research support
from the National Institute for Health and Research, the European Framework FP7, the Charles Wolfson
Curr Treat Options Neurol (2016) 18: 29 Page 9 of 12 29
Foundation, Action Medical Research (AMR), Vitaflo and SPARKS. She has sat on Advisory Boards for Vitaflo,
Sanofi, Eisai, Viropharma, and Zogenix for which remuneration is paid to her department.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, dis-
tribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and indicate if changes were made.
References and Recommended Reading
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Brodie MJ. Antiepileptic drug therapy the story so far.
Seizure. 2010;19:650–5.
2. Wheless JW. History of the ketogenic diet. Epilepsia.
2008;49 Suppl 8:3–5.
3. Lefevre F, Aronson N. Ketogenic diet for the treatment
of refractory epilepsy in children: a systematic review of
efficacy. Pediatrics. 2000;105, E46.
4. Keene DL. A systematic review of the use of the keto-
genic diet in childhood epilepsy. Pediatr Neurol.
2006;35:1–5.
5. Henderson CB, Filloux FM, Alder SC, Lyon JL, Caplin
DA. Efficacy of the ketogenic diet as a treatment option
for epilepsy: meta-analysis. J Child Neurol.
2006;21:193–8.
6. Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic
diet for the treatment of childhood epilepsy: a
randomised controlled trial. Lancet Neurol.
2008;7:500–6.
7.•• Sharma S, SankhyanN,Gulati S, Agarwala A. Use of the
modified Atkins diet for treatment of refractory child-
hood epilepsy: a randomized controlled trial.
Epilepsia. 2013;54:481–6.
Randomized controlled trial showing the efficacy and tolera-
bility of the modified Atkins diet in refractory childhood
epilepsies.
8. Pires ME, Ilea A, Bourel E, et al. Ketogenic diet for
infantile spasms refractory to first-line treatments: an
open prospective study. Epilepsy Res. 2013;105:189–94.
9. da Jung E, Kang HC, Kim HD. Long-term outcome of
the ketogenic diet for intractable childhood epilepsy
with focal malformation of cortical development. Pe-
diatrics. 2008;122:e330–3.
10. Thammongkol S, Vears DF, Bicknell-Royle J, et al. Ef-
ficacy of the ketogenic diet: which epilepsies respond?
Epilepsia. 2012;53:e55–9.
11.• Ramm-Pettersen A, Nakken KO, Skogseid IM, et al.
Good outcome in patients with early dietary treatment
of GLUT-1 deficiency syndrome: results from a retro-
spective Norwegian study. Dev Med Child Neurol.
2013;55:440–7.
Evidence of benefit in neurodevelopmental outcome of chil-
dren with GLUT-1 deficiency after early treatment with the
ketogenic diet.
12. Mullen SA,Marini C, Suls A, et al. Glucose transporter 1
deficiency as a treatable cause of myoclonic astatic
epilepsy. Arch Neurol. 2011;68:1152–5.
13. Arsov T, Mullen SA, Rogers S, et al. Glucose transporter
1 deficiency in the idiopathic generalized epilepsies.
Ann Neurol. 2012;72:807–15.
14. Hughes SD, Kanabus M, Anderson G, et al. The
ketogenic diet component decanoic acid increases
mitochondrial citrate synthase and complex I ac-
tivity in neuronal cells. J Neurochem.
2014;129:426–33.
15. Chang P, Terbach N, Plant N, Chen PE, Walker MC,
Williams RS. Seizure control by ketogenic diet-
associated medium chain fatty acids. Neuropharma-
cology. 2013;69:105–14.
16. Neal EG, Chaffe H, Schwartz RH, et al. A randomized
trial of classical and medium-chain triglyceride keto-
genic diets in the treatment of childhood epilepsy.
Epilepsia. 2009;50:1109–17.
17. Muzykewicz DA, Lyczkowski DA, Memon N, Co-
nant KD, Pfeifer HH, Thiele EA. Efficacy, safety,
and tolerability of the low glycemic index treat-
ment in pediatric epilepsy. Epilepsia.
2009;50:1118–26.
18. Loscher W, Schmidt D. Modern antiepileptic drug de-
velopment has failed to deliver: ways out of the current
dilemma. Epilepsia. 2011;52:657–78.
29 Page 10 of 12 Curr Treat Options Neurol (2016) 18: 29
19. Chiron C, Marchand MC, Tran A, et al. Stiripentol in
severe myoclonic epilepsy in infancy: a randomised
placebo-controlled syndrome-dedicated trial. STICLO
study group. Lancet. 2000;356:1638–42.
20. Kassai B, Chiron C, Augier S, et al. Severe myoclonic
epilepsy in infancy: a systematic review and a meta-
analysis of individual patient data. Epilepsia.
2008;49:343–8.
21. Nabbout R, Chiron C. Stiripentol: an example of
antiepileptic drug development in childhood epi-
lepsies. Eur J Paediatr Neurol. 2012;16 Suppl
1:S13–7.
22.• Guerrini R, Rosati A, Segieth J, Pellacani S, Bradshaw K,
Giorgi L. A randomized phase III trial of adjunctive
zonisamide in pediatric patients with partial epilepsy.
Epilepsia. 2013;54:1473–80.
Randomized phase III drug trial proving the tolerability and
effectiveness of zonisamide in the pediatric population leading
to licensing of the drug as adjunctive treatment in childrenwith
partial seizures.
23. Cross JH, Auvin S, Patten A, Giorgi L. Safety and toler-
ability of zonisamide in pediatric patients with epilep-
sy. Eur J Paediatr Neurol: EJPN: Off J Eur Paediatr
Neurol Soc. 2014;18:747–58.
24. Hanada T, Hashizume Y, Tokuhara N, et al.
Perampanel: a novel, orally active, noncompetitive
AMPA-receptor antagonist that reduces seizure activity
in rodent models of epilepsy. Epilepsia.
2011;52:1331–40.
25. Rosenfeld W, Conry J, Lagae L, et al. Efficacy and safety
of perampanel in adolescent patients with drug-
resistant partial seizures in three double-blind, place-
bo-controlled, phase III randomized clinical studies
and a combined extension study. Eur J Paediatr Neurol.
2015;19:435–45.
26. Biro A, Stephani U, Tarallo T, et al. Effectiveness and
tolerability of perampanel in children and adolescents
with refractory epilepsies: first experiences.
Neuropediatrics. 2015;46:110–6.
27. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol:
pharmacology and potential therapeutic role in epi-
lepsy and other neuropsychiatric disorders. Epilepsia.
2014;55:791–802.
28. Hussain SA, Zhou R, Jacobson C, et al. Perceived effi-
cacy of cannabidiol-enriched cannabis extracts for
treatment of pediatric epilepsy: a potential role for
infantile spasms and Lennox-Gastaut syndrome. Epi-
lepsy Behav: E&B. 2015;47:138–41.
29. Porter BE, Jacobson C. Report of a parent survey of
cannabidiol-enriched cannabis use in pediatric
treatment-resistant epilepsy. Epilepsy Behav.
2013;29:574–7.
30. Press CA, Knupp KG, Chapman KE. Parental
reporting of response to oral cannabis extracts for
treatment of refractory epilepsy. Epilepsy Behav.
2015;45:49–52.
31.• Epi KC, Epilepsy Phenome/Genome P, Allen AS, et al.
De novo mutations in epileptic encephalopathies. Na-
ture. 2013;501:217–21.
Whole exome sequencing in 264 patients with infantile spasms
or Lennox-Gastaud-syndrome revealed 329 causative de novo
mutations.
32. Veeramah KR, Johnstone L, Karafet TM, et al. Exome
sequencing reveals new causal mutations in children
with epileptic encephalopathies. Epilepsia.
2013;54:1270–81.
33.• Heron SE, Smith KR, Bahlo M, et al. Missense
mutations in the sodium-gated potassium channel
gene KCNT1 cause severe autosomal dominant
nocturnal frontal lobe epilepsy. Nat Genet.
2012;44:1188–90.
Whole exome sequencing of 4 patients with ADNFLE revealed
causative KCNT1 mutations.
34. Barcia G, Fleming MR, Deligniere A, et al. De novo
gain-of-function KCNT1 channel mutations cause ma-
lignantmigrating partial seizures of infancy. Nat Genet.
2012;44:1255–9.
35. McTague A, Appleton R, Avula S, et al. Migrating partial
seizures of infancy: expansion of the electroclinical,
radiological and pathological disease spectrum. Brain: J
Neurol. 2013;136:1578–91.
36.• Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of
function in 2 epilepsy phenotypes is reversed by quin-
idine. Ann Neurol. 2014;75:581–90.
The anti-arrhythmic drug quinidine, known to block KCNT1
channels is shown to reverse KCNT1 gain of function in mu-
tations knowing to cause ADNFLE and EIMFS.
37. Yang B, Gribkoff VK, Pan J, et al. Pharmacological
activation and inhibition of Slack (Slo2.2) channels.
Neuropharmacology. 2006;51:896–906.
38. Bearden D, Strong A, Ehnot J, DiGiovine M, Dlugos D,
Goldberg EM. Targeted treatment of migrating partial
seizures of infancy with quinidine. Ann Neurol.
2014;76:457–61.
39. Mikati MA, Jiang YH, Carboni M, et al. Quinidine in
the treatment of KCNT1 positive epilepsies. Annals of
Neurology 2015.
40. Bellini G, Miceili F, Soldovieri MV, et al. KCNQ2-
Related Disorder – Genereviews – NCBI Bookshelf,
2013: GeneReviews. Available at: http://www.ncbi.
nlm.nih.gov/bookshelf/br.fcgi?book=gene&-part=
bfns. Accessed June 2, 2015.
41. Porter RJ, Burdette DE, Gil-Nagel A, et al. Retigabine as
adjunctive therapy in adults with partial-onset seizures:
integrated analysis of three pivotal controlled trials.
Epilepsy Res. 2012;101:103–12.
42. Wang J, Li Y, Hui Z, et al. Functional analysis of po-
tassium channels in Kv7.2 G271Vmutant causing early
onset familial epilepsy. Brain Research 2015.
43. Hu HN, Zhou PZ, Chen F, Li M, Nan FJ, Gao ZB.
Discovery of a retigabine derivative that inhibits
KCNQ2 potassium channels. Acta Pharmacol Sin.
2013;34:1359–66.
Curr Treat Options Neurol (2016) 18: 29 Page 11 of 12 29
44. Pisano T, Numis AL, Heavin SB, et al. Early and effec-
tive treatment of KCNQ2 encephalopathy. Epilepsia.
2015;56:685–91.
45. Zhang Y, Kecskes A, Copmans D, et al. Pharmacologi-
cal characterization of an antisense knockdown
zebrafish model of Dravet syndrome: inhibition of
epileptic seizures by the serotonin agonist fenflur-
amine. PLoS ONE. 2015;10, e0125898.
46. Boel M, Casaer P. Add-on therapy of fenfluramine in
intractable self-induced epilepsy. Neuropediatrics.
1996;27:171–3.
47.•• Ceulemans B, Boel M, Leyssens K, et al. Suc-
cessful use of fenfluramine as an add-on treat-
ment for Dravet syndrome. Epilepsia.
2012;53:1131–9.
Use of fenfluramine as add-on treatment in patients with
Dravet syndrome led to seizure freedom in 70% of the treated
patients.
48. Pierson TM, Yuan H, Marsh ED, et al. mutation and
early-onset epileptic encephalopathy: personalized
therapy with memantine. Annals Clin Translat Neurol.
2014;1:190–8.
29 Page 12 of 12 Curr Treat Options Neurol (2016) 18: 29
